Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.
Bio-Rad Diabetes Division

Semiconductor-Based Nanopore Sequencing Platform Developed for Molecular Diagnostics

By Labmedica International staff writers
Posted on 24 Jan 2012
A startup company is developing a semiconductor-based nanopore-sequencing platform that will be used for molecular diagnostic applications.

Genia, the Mountain View (CA, USA)-based startup has an alpha version of its single-molecule platform in hand and is currently optimizing the biochemistry for a beta system.

Stefan Roever, CEO and founder of the company declined to provide a commercialization timeline for the system or details regarding expected read length or accuracy, but noted that he believes the platform will be able to sequence genomes at a cost "one order of magnitude less" than other single-molecule systems.

He described the system as a "single-molecule electrical detection sequencing platform," and said that the company expects it to be useful for targeted resequencing and molecular diagnostics that involve both human genomics and viral or bacterial DNA.

A number of other firms are developing nanopore sequencing systems, but Stephen Roever said that Genia's focus on the underlying chip platform sets it apart from competitors.

"We focused on operationalizing the nanopores," Stephen Roever said. "We essentially developed a way to create what are effectively lipid bilayer nanopore complexes, so the biological nanopore is a transmembrane protein that's suspended in a lipid bilayer."

The company has developed a way to "automatically set up whole arrays of [the nanopores] on the surface of a semiconductor chip and integrated circuit," ultimately making a "very complicated" process "massively scalable."

"We have a working platform and chip, and we have the basic building blocks on the biochemistry side. The next step is to take those and assemble them into a robust chemistry," said Mr. Roever. "That's where the focus is going to be and there's a significant amount of work still to be done there."

Related Links:

Genia



77 ELEKTRONIKA
DiagCor Bioscience
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: The Cobas 6000 Multipurpose Clinical Laboratory analyzer (Photo courtesy of Roche Diagnostics).

Low Density Lipoprotein Apolipoprotein-B Assay Validated

The relationship between apolipoprotein-B (Apo-B) concentration and the risk of developing cardiovascular disease (CVD) is more robust than the relationship between low density lipoprotein cholesterol... Read more

Microbiology

view channel

Novel Sequence Analysis Services Improve Pathogen Identification

A set of new-generation sequencing (NGS) services provides unique tools for more effective identification of known and unknown microorganisms, including bacterial, viral, fungal, and protozoan parasite pathogens. Aperiomics (Ashburn, VA, USA) has now introduced its breakthrough Absolute-NGS Pathogen Detection Platform... Read more

Industry News

view channel

Market for qPCR Exceeds USD 3 Billion

The market for real-time quantitative polymerase chain reaction (qPCR) was valued at about USD 3.2 billion for 2013 according to Kalorama Information (New York, NY, USA) an increase from USD 2.8 billion in 2011. The healthcare market researcher said that the testing system is considered the workhorse of research providing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.